Halozyme Therapeutics | HALO - Loan Capital

Stock Price
68.72
Daily Change
1.28 1.90%
Monthly
-1.22%
Yearly
28.57%
Q2 Forecast
65.77

Halozyme Therapeutics reported $1.94B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Baxter International USD 8.62B 852M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 247.21M 868.77M Mar/2026
DBV Technologies USD 0 0 Mar/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
MannKind USD 548.07M 371K Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024